HIV Infections, Toxoplasmosis, Cerebral
Conditions
Keywords
Sulfonamides, Toxoplasmosis, AIDS-Related Opportunistic Infections, Pyrimethamine, Drug Therapy, Combination, Encephalitis, Acquired Immunodeficiency Syndrome, Clindamycin
Brief summary
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.
Interventions
DRUGPyrimethamine
DRUGClindamycin
Sponsors
Palo Alto Medical Foundation
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Exclusion criteria
Co-existing Condition: Patients with the following conditions are excluded: * Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy. Patients with other opportunistic infections or brain diseases are excluded. Patients with AIDS and cerebral toxoplasmosis.
Countries
United States
Outcome results
None listed